Viactiv multivitamins
This article was originally published in The Tan Sheet
Executive Summary
Sampling of Chocolate Supreme and Tropical Fruit Splash multivitamin chews will take place Jan. 28 and 29 in 10 cities, according to McNeil Nutritionals. A direct mail program, ads in gyms and magazines, an FSI drop and web marketing also are planned for the full roll-out of Viactiv multivitamin chews to grocery, health, supermarket, club and mass merchandise stores. The products come in a 10-count to-go pack, retailing for $2.49; a 60-count canister that carries an SRP of $7.99-$8.99; and a 120-count club size, which costs $11.99-$12.99. Labeling states, "Just one chew a day provides essential vitamins and anti-oxidants to help maintain strong bones, activate energy and protect the health of your eyes, skin, heart and immune system." The chews debuted at the National Association of Chain Drugstores Marketplace in June (1"The Tan Sheet" July 5, 2004, p. 8)...
You may also be interested in...
NACDS In Brief
Bayer Alka-Seltzer Plus: Non-drowsy version of the cold medicine will begin shipping this month, Bayer says. The effervescent tablets come in a citrus blend flavor and contain 250 mg acetaminophen, 10 mg dextromethorphan hydrobromide and 5 mg phenylephrine HCI. The 20-tablet box will be line-priced with other Alka-Seltzer products and will be supported through both consumer and trade promotions, firm notes. Bayer also is adding its "easy open arthritis cap" feature to Aleve 40-count gelcaps, which will begin shipping in August. The new SKU will be easier to open than currently existing child-resistant packaging...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.